Thomas G. Brewer - Concepedia

Author

Thomas G. Brewer

Walter Reed Army Institute of Research ORCID

Also Known As

T BREWER, T Brewer, T G Brewer, T. Brewer, T. G. BREWER, T. G. Brewer, T.G Brewer, T.G. Brewer, THOMAS G. BREWER, Thomas Brewer

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

Walter Reed Army Institute of Research Armed Forces Research Institute of Medical Science Uniformed Services University of the Health Sciences Mahidol University Mahidol Oxford Tropical Medicine Research Unit

About

Thomas G. Brewer is an author at Walter Reed Army Institute of Research specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	23	1.7K
2	Health Sciences	3	3	178
3	Public Health	3	3	65
4	Social Sciences	2	2	105
5	Engineering	1	1	14

Thomas G. Brewer

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Rotavirus Vaccination and the Global Burden of Rotavirus Diarrhea Among Children Younger Than 5 Years Christopher Troeger, Puja C Rao, Shujin Cao, JAMA Pediatrics	2018	831
Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016 Christopher Troeger, Brigette F. Blacker, Puja C Rao, The Lancet Infectious Diseases	2018	673
Fatal Neurotoxicity of Arteether and Artemether Thomas G. Brewer, Stephen J. Grate, James O. Peggins, American Journal of Tropical Medicine and Hygiene Progressive SyndromeFatal NeurotoxicityMedicineHerbal MedicineHerb-drug Interaction	1994	269
Neurotoxicity in animals due to arteether and artemether Thomas G. Brewer, James O. Peggins, Stephen J. Grate, Transactions of the Royal Society of Tropical Medicine and Hygiene	1994	251
The Pharmacokinetics and Bioavailability of Dihydroartemisinin, meether, Artemether, Artesunic Acid and Artelinic Acid in Rats Qi-Gui Li, James O. Peggins, Lawrence Fleckenstein, Journal of Pharmacy and Pharmacology Pharmaceutical ScienceArtesunic AcidPharmacotherapyPhysiologically-based Pharmacokinetic ModelingPharmacodynamic Modeling	1998	164
Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Reynaldo Dietze, Sandra Carvalho, Luiz Carlos Pedrosa Valli, American Journal of Tropical Medicine and Hygiene Unusual Clinical FeaturesAfrican TrypanosomiasisAntiparasitic AgentParasitic ProtozoaLeishmania Chagasi	2001	126
Neurotoxicity of artemisinin analogs in vitro David Wesche, Mark A. DeCoster, Frank C. Tortella, Antimicrobial Agents and Chemotherapy Discrete DistributionGliomaMedicineHerbal MedicineExperimental Neuropathology	1994	113
Efficacy of Monthly Tafenoquine for Prophylaxis of<i>Plasmodium vivax</i>and Multidrug‐Resistant<i>P. falciparum</i>Malaria Douglas S. Walsh, Chirapa Eamsila, Theerayuth Sasiprapha, The Journal of Infectious Diseases Drug SafetyThai SoldiersPlacebo RecipientsClinical Infectious DiseaseAntiparasitic Agent	2004	103
Randomized Trial of 3-Dose Regimens of Tafenoquine (WR238605) versus Low-Dose Primaquine for Preventing Plasmodium vivax Malaria Relapse Douglas S. Walsh, Polrat Wilairatana, D. B. Tang, Clinical Infectious Diseases	2004	100
Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. James M. Grace, A. J. AGUILAR, K. M. Trotman, PubMed Pharmaceutical ScienceComplicated MalariaMalariaRecombinant Cytochrome P450Hepatotoxicity	1998	97

Page 1